Grace Therapeutics (GRCE) Price/OCF Ratio: History & Chart

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T20:36:43.205Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:36:43.205Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 33,605,864
TTM operating cash flow · period ending 2026-06-30: -10,300,639

FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

GRCE Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

GRCE Competitors' Price/OCF Ratio

GRCE

Grace Therapeutics, Inc.

Current

Market Cap

$33.61M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SCLX

Scilex Holding Company

vs GRCE

Market Cap

$33.63M

Price/OCF Ratio

N/A

TTM Avg

5.50

3Y Avg

5.64

5Y Avg

5.64

ALGS

Aligos Therapeutics, Inc.

vs GRCE

Market Cap

$33.29M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BDMD

Baird Medical Investment Holdings Limited

vs GRCE

Market Cap

$32.93M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELUT

Elutia Inc

vs GRCE

Market Cap

$34.35M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEPH

Nephros, Inc.

vs GRCE

Market Cap

$32.79M

Price/OCF Ratio

N/A

TTM Avg

33.35

3Y Avg

46.22

5Y Avg

46.22

BEAT

HeartBeam, Inc.

vs GRCE

Market Cap

$32.42M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BCTX

BriaCell Therapeutics Corp.

vs GRCE

Market Cap

$34.97M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QTI

QT Imaging Holdings, Inc.

vs GRCE

Market Cap

$35.52M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NSYS

Nortech Systems Incorporated

vs GRCE

Market Cap

$31.52M

Price/OCF Ratio

10.28

TTM Avg

11.37

3Y Avg

193.26

5Y Avg

145.59

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Grace Therapeutics, Inc. (GRCE)	$33.61M	N/A	N/A	N/A	N/A
Scilex Holding Company (SCLX)vs ›	$33.63M	N/A	5.50	5.64	5.64
Aligos Therapeutics, Inc. (ALGS)vs ›	$33.29M	N/A	N/A	N/A	N/A
Baird Medical Investment Holdings Limited (BDMD)vs ›	$32.93M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$34.35M	N/A	N/A	N/A	N/A
Nephros, Inc. (NEPH)vs ›	$32.79M	N/A	33.35	46.22	46.22
HeartBeam, Inc. (BEAT)vs ›	$32.42M	N/A	N/A	N/A	N/A
BriaCell Therapeutics Corp. (BCTX)vs ›	$34.97M	N/A	N/A	N/A	N/A
QT Imaging Holdings, Inc. (QTI)vs ›	$35.52M	N/A	N/A	N/A	N/A
Nortech Systems Incorporated (NSYS)vs ›	$31.52M	10.28	11.37	193.26	145.59

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

GRCE Price/OCF Ratio Metrics

GRCE Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics